tradingkey.logo

Neuropace Inc

NPCE
查看詳細走勢圖
16.020USD
-0.170-1.05%
收盤 12/26, 16:00美東報價延遲15分鐘
533.16M總市值
虧損本益比TTM

Neuropace Inc

16.020
-0.170-1.05%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.05%

5天

-3.44%

1月

-2.91%

6月

+49.58%

今年開始到現在

+43.16%

1年

+50.14%

查看詳細走勢圖

TradingKey Neuropace Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Neuropace Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名47/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價17.50。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Neuropace Inc評分

相關信息

行業排名
47 / 207
全市場排名
147 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 8 分析師
買入
評級
17.500
目標均價
+6.51%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Neuropace Inc亮點

亮點風險
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
業績高增長
公司營業收入穩步增長,連續3年增長75.54%
業績增長期
公司處於發展階段,最新年度總收入79.91M美元
估值低估
公司最新PE估值-21.36,處於3年歷史低位
機構減倉
最新機構持股31.14M股,環比減少8.66%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉3.00K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.28

Neuropace Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Neuropace Inc簡介

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
公司代碼NPCE
公司Neuropace Inc
CEOBecker (Joel D)
網址https://www.neuropace.com/

常見問題

Neuropace Inc(NPCE)的當前股價是多少?

Neuropace Inc(NPCE)的當前股價是 16.020。

Neuropace Inc 的股票代碼是什麼?

Neuropace Inc的股票代碼是NPCE。

Neuropace Inc股票的52週最高點是多少?

Neuropace Inc股票的52週最高點是18.975。

Neuropace Inc股票的52週最低點是多少?

Neuropace Inc股票的52週最低點是7.563。

Neuropace Inc的市值是多少?

Neuropace Inc的市值是533.16M。

Neuropace Inc的淨利潤是多少?

Neuropace Inc的淨利潤為-27.14M。

現在Neuropace Inc(NPCE)的股票是買入、持有還是賣出?

根據分析師評級,Neuropace Inc(NPCE)的總體評級為買入,目標價格為17.500。

Neuropace Inc(NPCE)股票的每股收益(EPS TTM)是多少

Neuropace Inc(NPCE)股票的每股收益(EPS TTM)是-0.750。
KeyAI